Arvind Chaudhry, MD
Hematology & Oncology · Spokane, WANPI 1750336236
Payments from drug & device makers
Across 3,056 payments — averaging $3749.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$3.5M
- Alkermes, Inc.$1.5M
- Exelixis Inc.$1.1M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Merck$966K
- Bayer$680K
- plus $2.6M from 54 others
Across 8 payments — averaging $2427.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Eli Lilly$286
- AbbVie$120
What the payments were for
- Consulting fees$8,67312%
- Speaking & faculty fees$18,48526%
- Travel & lodging$7,21810%
- Food & beverage$32,69046%
- Education$2,7514%
- Other$1,2632%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,457,136 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 90 | $1,402,759 |
| CabometyxCabozantinib S-Malate | 38 | $963,702 |
| BrukinsaZanubrutinib | 54 | $622,589 |
| XtandiEnzalutamide | 46 | $601,188 |
| JakafiRuxolitinib Phosphate | 41 | $600,176 |
| TagrissoOsimertinib Mesylate | 23 | $366,196 |
| IbrancePalbociclib | 22 | $344,122 |
| BosulifBosutinib | 21 | $339,541 |
| RevlimidLenalidomide | 18 | $335,160 |
| VonjoPacritinib Citrate | 12 | $316,785 |
| SprycelDasatinib | 17 | $282,565 |
| CalquenceAcalabrutinib Maleate | 30 | $282,198 |
| PomalystPomalidomide | 12 | $275,430 |
| VerzenioAbemaciclib | 18 | $267,221 |
| InrebicFedratinib Dihydrochloride | 13 | $145,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $51,622 | $1,402,75990 claims |
| Exelixis Inc.Cabometyx | $1,122,656 | $963,70238 claims |
| PfizerIbrance, Bosulif, Eliquis | $177,452 | $727,370118 claims |
| AstraZenecaTagrisso, Calquence | $40,340 | $648,39453 claims |
| Beigene USA, Inc.Brukinsa | $174 | $622,58954 claims |
| Astellas Pharma US IncXtandi | $2,096 | $601,18846 claims |
| Incyte CorporationJakafi | $829 | $600,17641 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $1,051,945 | $557,99429 claims |
| Bristol Myers SquibbRevlimid, Inrebic | $27,191 | $480,58731 claims |
| Lilly USA, LLCVerzenio | $834 | $267,22118 claims |
| AbbVieLupron Depot | $86,719 | $98,61814 claims |
| Johnson & JohnsonXarelto | $5,562 | $39,84852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Spokane
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Sibel BlauPuyallup$11.9M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.